CN106038791A - Medicine composition for treating posterior circulation ischemia syndrome and preparation method thereof - Google Patents

Medicine composition for treating posterior circulation ischemia syndrome and preparation method thereof Download PDF

Info

Publication number
CN106038791A
CN106038791A CN201610505361.0A CN201610505361A CN106038791A CN 106038791 A CN106038791 A CN 106038791A CN 201610505361 A CN201610505361 A CN 201610505361A CN 106038791 A CN106038791 A CN 106038791A
Authority
CN
China
Prior art keywords
ethanol
pharmaceutical composition
rhizoma
posterior circulation
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201610505361.0A
Other languages
Chinese (zh)
Inventor
庞大坤
孔倩倩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan Xingyi Medical Technology Co Ltd
Original Assignee
Jinan Xingyi Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Xingyi Medical Technology Co Ltd filed Critical Jinan Xingyi Medical Technology Co Ltd
Priority to CN201610505361.0A priority Critical patent/CN106038791A/en
Publication of CN106038791A publication Critical patent/CN106038791A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A61K36/12—Filicopsida or Pteridopsida
    • A61K36/126—Drynaria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/79—Schisandraceae (Schisandra family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a medicine composition for treating posterior circulation ischemia syndrome and a preparation method thereof. The medicine composition is prepared from the following medicinal raw mateirals: fagopyr um dibotrys hara, tetrapanax papyriferus, schisandra chinensis, rhizoma drynariae, radices ligustici sinensis, aluminum trilinoleate and woodfordin A according to a proportion. Various preparations can be prepared from the medicine composition according to a conventional preparation process. The medicine composition has a remarkable treatment effect on posterior circulation ischemia syndrome treatment.

Description

Pharmaceutical composition for the treatment of Posterior circulation ischemia syndrome and preparation method thereof
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to a kind of pharmaceutical composition treating Posterior circulation ischemia syndrome and Its preparation method.
Background technology
Posterior circulation ischemia refers to metacyclic carotid artery system transient ischemic attack (TIA) and cerebral infarction.Its synonym Including vertebral basilar system ischemia, metacyclic TIA and cerebral infarction, Vertebral-basilar artery disease, Vertebral-basilar artery thromboembolism Property disease.In view of MRI diffusion-weighted imaging finds that the Posterior circle TIA of about half has clear and definite infarction change and TIA and cerebral infarction Boundary more and more fuzzyyer, therefore contain metacyclic TIA and cerebral infarction, beneficially clinical manipulation with Posterior circulation ischemia.After follow The understanding history of ring ischemia: the fifties in last century, finds that some TIA patients have Serious Stenosis or the obturation of extracranial carotid arteries, Supposition is therefore and causes vascular territory tissue only by Doppler flow mapping blood supply, is in relative ischemia state, is referred to as " carotid artery blood supply Not enough ".This concept is amplified Posterior circle, creates the concept of " vertebro-basilar artery insufficiency ".Visible, classical vertebra substrate Cerebral arterial insufficiency concept has two implications, refers to metacyclic TIA clinically, the cause of disease refers to large artery trunks Serious Stenosis or closes The hemodynamics Low perfusion that plug causes.After 20 century 70s, specify carotid artery system ischemia and only have TIA and infarction two kinds Form, " carotid artery blood supply insufficiency " concept i.e. not in use by.But, delayed due to recognize Posterior circulation ischemia, vertebra substrate is moved Arteries and veins blood supply insufficiency concept is still widely used, and produces some inapt understanding: as how dizziness, dizziness being attributed to vertebra substrate Cerebral arterial insufficiency;By hyperosteogeny of cervical vertebra as the Important cause of disease of vertebro-basilar artery insufficiency;More have Vertebral-basilar artery The concept of blood supply insufficiency is extensive, it is believed that it is the state of a kind of the most improper but also non-ischemia.These situations are particularly acute in China, Cause that vertebro-basilar artery insufficiency concept is unclear, diagnostic criteria is failed to understand, it is lack of standardization to dispose.
The drug main for the treatment of Posterior circulation ischemia syndrome to have at present: Folium Ginkgo extract sheet, and Folium Ginkgo capsule, Radix Notoginseng are led to Relieving capsule, nicergoline tablets etc..Though these medicines have certain curative effect, but effect is the most of great satisfaction.
Radix Et Rhizoma Fagopyri Tatarici: [source] buckwheat plant sky Semen Fagopyri Esculenti Fagopyrum dibotrys (D. Don) Hara., with Root stock is used as medicine.Autumn uproots, and dries.[nature and flavor] are pungent, bitter, cool.[function cures mainly] heat-clearing and toxic substances removing, promoting blood circulation to remove blood stasis, invigorating spleen to remove dampness. For laryngopharynx swelling and pain, lung abscess, empyema, pneumonia, stomachache, hepatitis, dysentery, dyspepsia, night sweat, dysmenorrhea, amenorrhea, leucorrhea；Outward With controlling tuberculous lymphadenitis, carbuncle furuncle and phyma poison, traumatic injury.[extracts] " whole nation Chinese herbal medicine compilation ".
Medulla Tetrapanacis: [source] this product is Araliaceae rice-paper plant Tetrapanax papyriferus (Hook.) K. The dry stem pith of Koch.Extracting stem, the section of being cut into autumn, take advantage of fresh taking-up marrow, reason is straight, dries.[character] this product is cylinder, Long 20～40cm, diameter 1～2.5cm.Superficial white or faint yellow, has shallow groove stricture of vagina.Body is light, and matter is soft, slightly elastic, easy to break Disconnected, section is smooth, aobvious silvery white gloss, and there are the hollow of diameter 0.3～1.5cm or translucent thin film in middle part, and vertical section is ladder Shape arranges, and solid person is rare.Odorless, tasteless.[nature and flavor] are sweet, light, are slightly cold.[return through] attaches to the lung and stomach meridians.[function cures mainly] heat clearing away profit Urine, stimulating milk secretion of ventilating.For hygropyrexia dark coloured urine, the puckery pain of gonorrhea, edema oliguria, agalactia.[extracts] " Chinese Pharmacopoeia ".
Fructus Schisandrae Chinensis: [source] is the fruit of Drymotaenium miyoshianum (Mak.) Mak. kind plant Fructus Schisandrae Chinensis.Pluck during fruit full maturity after the Frost's Descent, pick fruit Branch and impurity, dry；Storage is dried ventilation, prevents from going rotten, damaging by worms.[original shape state] Fructus Schisandrae Chinensis, has another name called: face rattan, Fructus Zanthoxyli Plansipini.Fall Leaf woody climber, up to 8 meters.Peel of stem taupe, hole skin is obvious, and sprig brown slightly has corner angle.Leaf alternate, handle is elongated；Blade is thin And band film quality；Obovate avette, wealthy is so that oblong, long 5～11 centimetres, wide 3～7 centimetres, tip point, base portion wedge shape, wealthy Wedge shape is to circular, and there is small tooth at edge, above green, below faint yellow, have fragrance.Flower unisexuality, dioecism；Male flower tool is long Stalk, perianth 6～9, oval, stamen 5, base portion symphysis；Female flower perianth 6～9, gynoecium is most, and helical arrangement is on holder, sub Room falls pyriform, and without style, after being pollinated, holder gradually extends into spike.Berry is spherical, diameter 5～7 millimeters, is dark red time ripe Color, includes seed 1～2 pieces.Florescence 5～July.Really phase 8～JIUYUE.[character] dry fruit is slightly spherical or oblate spheroid, diameter 5 ～8 millimeters.Crust cerise, aubergine or kermesinus.Aobvious glossy, there is irregular shrinkage.Softness, constant adhesion one in fruit Rise；Include seed 1～2 pieces, kidney shape, brown color, glossy, hard, kernel white.Sarcocarp feeble QI is weak and special, sour in the mouth.Seed Have fragrance after Po Sui, acrid in the mouth and bitter.With aubergine, grain is big, meat is thick, have oiliness and gloss person to be preferred.[chemical composition] contains the five tastes Son element (schizandrin), deoxidation schizandrin (de-oxyschizandrin), new son element simply (neoschizandrin), schisandrol (schizan-drol), schizantherin (schisantherin, gomisin), A, B, C, D, E, F, G, H, J, K1, K2, K3, L1, L2, M1, M2, N2, O, R etc..[pharmacological action] can improve normal person and persons suffering from ocular disorders Vision and expand the visual field；Audition is also had good impact, states the discriminative power that can improve skin receptor.[nature and flavor] acid, temperature. 1. " herbal classic ": " sour in the mouth, temperature." 2. " not Lu ": " be nontoxic." 3. Tang Materia Medica: " sweet acid of skin and flesh, arduous in core, there is saline taste."④ " Changsha medicine solution ": " the micro-hardship of sour in the mouth is salty, and gas is puckery." [returning through] enter lung, kidney channel, 1. Materia Medica of Decoction: " starts with lunar, the few the moon of foot Warp." 2. " detailed outline ": " enters liver, the heart." [function cures mainly] astringes the lung, and nourishing kidney is promoted the production of body fluid, and receives antiperspirant, arresting seminal emission.Controlling the deficiency of the lung to breath with cough, xerostomia is made Yearningly, spontaneous perspiration, night sweat, impairment caused by overstrain weakness and emaciation, emission, chronic diarrhea chronic dysentery.1. " herbal classic ": " main QI invigorating, cough with dyspnea, the thin degree of impairment caused by overstrain, mend Deficiency, reinforcing YIN-essence, benefit man's essence." 2. " not Lu ": " supports the five internal organs, heat extraction, flesh in raw the moon." 3. " Japan hanako materia medica ": " improving eyesight, warm water Dirty, control wind, the therapeutic method to keep the adverse QI flowing downwards, help digestion, cramp caused by acute vomiting and diarrhea, mass beside the umbilicus renal mass cold air, consumer edema, regurgitation, trusted subordinate's flatulence, quench the thirst, heat clearing away and restlessness relieving, relieves the effect of alcohol Poison, strengthening bone and muscle." 4. Li Gao: " promoting the production of body fluid to quench thirst.Controlling dysentery, invigorating primordial QI is not enough, receives the gas of dissipation, platycoria." 5. Wang Haogu: " Control dry coughing of breathing with cough, Zhuan Shui town sun." 6. " book on Chinese herbal medicine covers bamboo fish trap ": " cough due to wind and cold, the south five tastes are strange, deficient impairment caused by overstrain, and north five is hidden the most wonderful." 7. " explaining abstruseness of the canon of materia medica ": " controlling nocturnal emission with astringent drugs, arresting sweating." [extracts] " Chinese medicine voluminous dictionary ".
Rhizoma Drynariae: [source] is Drynariaceae plant Mongolian oak Herba pteridii latiusculi, Qinling Mountains Mongolian oak Herba pteridii latiusculi and light leaf Mongolian oak Herba pteridii latiusculi, the rhizome of precipice Rhizoma Zingiberis Recens Herba pteridii latiusculi.Annual equal Can excavate, remove silt, be dried, or the shape scale that sings the hair.[original shape state] 1. plant height 25-40cm.Root stock grows wild, thick shape meat Matter, close drilled shape drapes over one's shoulders pin table scale, has green hair.Leaf two type；The trophophyll taupe brown of Folium Querci dentatae shape, avette, stockless, dry film matter is long 5-7cm, wide about 3.5cm, base portion is heart-shaped, is backed with thin undercoat, and there is superficial splitting at edge；Sporophyll is tall and big, papery, green, without hair, Oblong, wide 14-18cm, corrugate, the winged short handle of downward one-tenth to base portion stenosis, more than middle part deep plumage splits；Sliver 7-13 pair, slightly tiltedly on, long 7-10cm, wide 2-3cm, mucro, there is unconspicuous thin cognate at edge；Netted veins, two sides is the most obvious. Sporangiorus is circular, on the cross point being born in built-in scun.2-3 row is respectively lined up along Zhong Mai both sides；Without indusium.2. plant is high 20-50cm.Root stock grows wild, meat, the most about 1cm, close by rufous, lanceolar scale.Leaf two type；Have thin along rachis and vein Undercoat, trophophyll is rare, and long round shape lanceolar, deep plumage splits；Sporophyll has the handle of narrow wing, and base portion has joint；Blade is wealthy drapes over one's shoulders pin Shape, long 20-40cm, middle part width 5-10cm, deep plumage splits and several reaches rachis, two sides along vein and rachis by white undercoat；Sliver 20-30 Right；Wide 5-15mm, blunt tip, edge tool incises shape according to tooth；Vein is obvious.Sporangiorus is circular, the friendship being born in built-in scun On crunode.1 row is respectively become in Zhong Mai both sides；Without indusium.3. plant is up to 60cm. root stock meat, grows wild, by opaque brown The lanceolar scale of color.Leaf two type, without hair；Trophophyll is wealthy avette, long 8-15cm, wide 5-10cm, and shallow plumage splits to deep plumage and splits；Spore The long 8-20cm of leaf petiole, base portion with joint and is born on root stock；The long 25-45cm of blade, Long Circle or the avette tip of long round shape Short tapering, base portion width 20-30cm, pinniform drastic crack reaches rachis；Sliver lanceolar, alternate, two sides is smooth, and edge is the thickest, has thin Shallow incise；Net-veined leaf veinclearing shows.Lid without sporangiorus.4. plant height 80-140cm.The thick shape of root stock, close by the linear squama of brown length Sheet.Leaf one type, the Gao Cong of bunch generation circular hollow；The long 80-140cm of blade, tip is tapering, the narrowest below middle part, but nearly base portion Again gradual change width and in heart, more than middle part deep plumage splits, and is the most gradually cleaved into shape, two sides Glabrous, Quan Yuan；Vein is netted, two sides Substantially, there is the single or scun of bifurcated in mesh.Sporangiorus and is born in scun infall, has 1 row between every offside feeling pulse, circular Or generally the 3rd time scun of bath extends, in broken string shape time ripe.Spore is oval, and sporoderm tool spinule or tubercle bulk stricture of vagina, without capsule Group's lid.[character] character identification 1. surface is close by the tiny scale of brown or rufous, and the person of being close to is in film quality peltate；Directly do not stretch person to drape over one's shoulders Aciculiform, tip point, marginal tassel shape (eyelashes), and in middle handle base portion and rhizome tender end comparatively dense.Scale comes off and locates aobvious brown, can See tiny longitudinal texture and ditch ridge.There is stipe scar above, have longitudinal ridge stricture of vagina and radicula trace below.Matter is hard, section rufous, has white Color meristele, lines up long oblateness.Gas is fragrant, micro-sweet, the 2. scale strip lanceolar of taste, shows taupe at scale dehumidification, and tool is thin Little longitudinal texture.Section brown color, canescence, point-like meristele lines up ellipse.Gas is fragrant, puckery.3. scale rufous, leather Matter, triangle, imbricate arranges, and nearly base portion peltate raw, is close to rhizome surface.Matter is crisp, and section meristele lines up ellipse. Makings, salty in the mouth is puckery.4. rhizome is cylindrical, surface close by strip lanceolar soft scale, scale comes off the aobvious puce in place, has The longitudinal ditch ridge differed in size and tiny texture.Section brown, point-like meristele lines up similar round.QI exhaustion is micro-, puckery.All with Bar is thick, brown person is preferred.[chemical composition] Drynaria fortunei(Kunze) J.Smith rhizome (naringin) Han naringin, 21-hopenen (hop-21-ene), 9(11) fernene [fern-9(11) ene], 7-fernene (fern-7-ene) 3-wild goose tooth alkene (filic-3-ene), β-paddy steroid Alcohol (β-sitosterol), stigmasterol (sting-masterol), oil recovery sterol (campesterol) and tetracyclic triterpenes chemical combination Thing: ring jackfruit sterol-acetas (cycloardenyl acetate), ring Rhizoma Polypodiodis Nipponicae steryl acetate (cy- Clomargenyl acetate), cyclolaudenol acetas (cyclolaudenylacetaet), 9,10-ring Pilus Caprae seu Ovis steroid- 25-enol-3 β-acetas (9,10-cycloanost-25-en-3 β-yl acetate).Precipice Rhizoma Zingiberis Recens Herba pteridii latiusculi rhizome hopenen Han 21-, 13(18) neohopene [neohop-13 (18)-ene], 9(11)-fernene, cupreol, stigmasterol, campesterol and Fourth Ring Triterpenoid compound: ring jackfruit steryl acetate, ring Rhizoma Polypodiodis Nipponicae sterol enolacetate, cyclolaudenol acetas, 9, 10-ring Pilus Caprae seu Ovis steroid-25-enol-3 β-acetas.[pharmacological action] is 1. studied according to China Medicine University's week copper water etc., Drynaria fortunei(Kunze) J.Smith rhizome Water decoction (20g/kg, 30g/kg) and naringin (the most former medicine 20g/kg) gavage have rush to the healing of experimental rat bone injury Enter effect.2. Rhizoma Drynariae water decoction 7.5-50g/kg gavage, has stimulation bone articular cartilage cell to Rat Experimental arthritis Compensatory hypertrophy effect, and can partly improve owing to the change of mechanical stress line causes the degeneration of articular cartilage, thus reduce Osteoarthritis variability.3. Rhizoma Drynariae flavanone glycoside can increase the Beating Rate of In vitro culture rat neonatal rat myocardial cell, makes Shrink strong, and myocardial cell is had pace-making effect, its mechanism of action, a kind of beta-receptor agonist may be similar to.4. Rhizoma Drynariae Decocting liquid (100%) 0.8ml/kg is administered orally, to Experimental Hyperlipemia rabbit can the rising of substantially prophylactic serum cholesterol, triglyceride, And the formation of aorta wall atherosclerotic plaque can be prevented.5. guinea-pig studies prompting, Rhizoma Drynariae decoct and kanamycin share can Alleviate the kanamycin toxic action to cochlea, but the development of toxic deafness after drug withdrawal can not be controlled.6. Rhizoma Drynariae decoct exists Staphylococcic growth can be suppressed in test tube.[nature and flavor] are bitter；Warm in nature.[return through] liver；Kidney channel.[function cures mainly] the kidney invigorating bone strengthening；Live Blood and relieving pain.Main lumbago due to renal deficiency；Foot and knee flaccidity；Deaf；Toothache；Chronic diarrhea；The enuresis；Injury and bone fracture and alopecia areata.[extracts] " China is originally Grass ".
Rhizoma Ligustici: [source] is samphire Rhizoma Ligustici and the rhizome of Rhizoma Ligustici and root.Plant and can gather in the crops for 2 years.At 9-10 The moon falls after Seedling, takes under ground portion, removes earth and residual stem, dries or a heatable brick bed is done.[original shape state] perennial herb, up to 1m.Root Stem is flourishing, the tuberosity that tool expands.Stem is upright, cylindrical, and hollow has vertical straight flute stricture of vagina.Basal leaf tool long handle, handle length is up to 20cm； The ripe wide triangle of blade wheel, long 10-15cm, wide 15-18cm, go out formula pinniform two times three and totally cleave, first time long round shape of accessory pinna profile Avette, long 6-10cm, wide 5-7cm, bottom accessory pinna tool handle, the long 3-5cm of handle, base portion slightly expands；It is avette that sliver is returned at end, is about 3cm, Width about 2cm, tip is tapering, and shape is shallow splits for edge tool, has small cusp, and, without hair, only there is pubescence on two sides on arteries and veins, the raw pinnule tip in top Tapering to shape of tail；Stem middle leaf is bigger；The nearly stockless of stem upper leaf, base portion enlarges into the sheath of avette armful of stem.Universal umbel top is raw Or side is raw；Phyllary 6-10, linear to pinniform checking, it is about 6mm；Umbrella spoke 14-30, up to 5cm, four prismatics, there is short rough hair；Little Umbrella inflorescence has involucel agreement that contracts a film or TV play to an actor or actress 10, linear or narrow lanceolar, long 3-4mm；Spend little, without calyx tooth；Petal is in vain with, obovate, first End nick, has infolding small cusp；Stamen 5；Style Keelung is risen, and style is long, outside contrary flexure.Diachenium is oval avette, is about 4mm, Wide 2-2.5mm, tip is narrow, mitogenetic fruit heel projection, and incline is expanded into aliform, has oil pipe 1-3, in incline rib groove in heel rib groove Having oil pipe 3, there is oil pipe 4-6 in symphysis face, and the endosperm outside of belly is straight.The month at florescence 7-9, really the phase 9-10 month.Perennial herb, high 30- 80cm.Rhizome is relatively known；Root cone, bifurcated, surface dark brown.Stem is upright, cylindrical, hollow, and there is vertical stripe on surface, and normal band is purple Color.Leaf tool handle, basal leaf petiole is up to 19cm, goes out formula pinniform two to three times three and totally cleave, first time sliver 4-6 pair, the most lower a pair There is longer handle, the long 2-5cm of handle；Second time normal stockless of sliver；It is avette avette to Pedicellus et Pericarpium Trapae shape that sliver is returned at end, long 2-3cm, wide 1-2cm, Base portion is heart-shaped, and to wedge shape, the normal 3-5 in edge is shallow to be split, sliver tool tooth, and increment has apiculiform inflorescence top raw or side is raw, diameter 3-7cm；Always Bract 2, linear, it is about 1cm, by rough hair, the narrow film quality in edge, caducous；Umbrella spoke 8-16, long 2-3cm；Involucel sheet 8-10, bores shape, Long 3-5mm, by rough hair；Umbellule has colored 15-20；Calyx tooth is inconspicuous；Petal white, long round shape obovate, tool infolding is little Tongue piece；Style Keelung is risen, hemispherical, and style is long, really phase downward contrary flexure.Diachenium is oval, long 3-4mm, wide 2-2.5mm, point Fruit heel projection, the narrow aliform of incline, there is oil pipe 1 in rib groove, be 2, symphysis face 2-4 less, the endosperm outside of belly is straight.The month at florescence 7-9, The really phase 9-10 month.[character] character identification (1) Rhizoma Ligustici rhizome is that irregular nodular pattern is cylindrical, slightly distorts, slightly branch, long 3-10cm.Surface common brown burgundy, coarse, there is vertical wrinkle, cork easily peels off, and upper end has one to several circular hole stem foots, There is root trace and the undesirable root of most spot-like projections downside.Body is light, and matter is harder, frangibility, section yellow or yellow-white, fibroid.Gas Giving off a strong fragrance, acrid in the mouth, hardship, micro-fiber crops.(2) Rhizoma Ligustici rhizome in do not advise by lumps or column, long 2-10cm, diameter 0.5- 1.5cm.Surface sepia, there is the joint of phyllopodium and the projection grown thickly upper end, and there is the root of most elongate curved lower end.(2) Rhizoma Ligustici Similar to Rhizoma Ligustici, but phloem grease chamber diameter 45-200 μm, xylem vessel's diameter 10-27 μm, wood fiber mass-sending reaches, nearly center Being surrounded by 3-4 row cork cell of having of groups of fibers.Marrow tool minority grease chamber.[chemical composition] 1. Rhizoma Ligustici contains volatile oil 0.85%, main constituent is: neocindilide (neocindilide) accounts for 25%, and limonene (limonene) accounts for 14.44%, in cnidium monnieri Ester (cnidilide) accounts for 10.78%, and 4-terpineol (4-terpineol) accounts for 8.0%；Also contain: acetic acid 4-Oleum Pini alcohol ester (4- Terpinyl acetate), Palmic acid (palmitic acid), eneα-cedar (α-cedrene), β-, ξ-selinene (selinene), 2,3-bis-chloro-4-methylfurans (2,3-dihydro-4-methylfuran), enanthaldehyde (heptanal), α pinane Alkene (α-pinene), 3-carene (△ △ 2-carene), sabinene (sabinene), β-ocimene-Y(β-ocimene-Y), different Terpinene (terpinolone), isovaleric acid-3-methyl butyl ester (3-methyl-butlisovalerate), to methoxyl group second Acyl benzophenone (p-methoxyacetophenone), α-and beta-elemene (el-emene), ξ-guaiene (ξ-guaiene), snow Pine alkene (himachalene), γ-cadinene (γ-cadinene), myristicin (myristicin), 9,10-ten eight carbon two Olefin(e) acid (9,10-octadecadienoic acid) [1] etc..Separately have been reported that, volatile oil contains: α-and nopinene, sabinene, Camphor tree Alkene (camphene), myrcene (myrcene), 3-carene, α-and β-phellandrene (phellandrene), to P-cymene (p- Cymene), α-and γ-terpinene (terpinene), terpinolene, 1-epoxide-4-methylbenzene (1-ethoxyl-4-methyl- Benene), Camphora (camphor), penta benzene (pent-ylbenzene), 4-terpineol, lavandulol (lavandulol), α-pine Oleyl alcohol (α-terpineol), myrtanol (myrtenol), cordovan life whip oxalene ketone (verbenone), nerol (nerol), Neral (neral), geraniol (geraniol), geranial (geranial), borneol acetate (bornylacetate), acetic acid-4-Oleum Pini alcohol ester carvacrol (carvacrol), α-(king is ancient) (king's bar) alkene (α- Copaene), beta-elemene, β-Flos Caryophylli alkene (β-caryophyllene), α-and β-farnesene (farnesene), aromadendrene (aromadendrene), α oxalene (α-humulene), α-curcumene (α-curcum-ene), γ-muurolene (γ- Muurolene), γ-patchoulene (γ-patchoulene), β-selinene, β-cadinene (β-cadinene), different lima bean Cool ether (isomyristicin), elemicine (elemincin), 3-butylidenephthalide (3-cadinene phtylidene), Neocindilide [2] etc., Rhizoma Ligustici also (3-butylidene4,5-Han 3-butylidene-4,5-dihydrophthalide Dihydrophthalide), sucrose (sucrose) [3], formic acid dimethyl ester (dimethylp-phthalate) dry to benzene, river, ocean Vault lactone (senkyunolide) A, G, H, I, cupreol (β-sitosterol) [4], ferulic acid (ferulicacid) [5] .2. Rhizoma Ligustici contains volatile oil 1.3%, and main constituent is: β-phellandrene accounts for 33.32%, and acetic acid 4-Oleum Pini alcohol ester accounts for 13.82%, Semen Myristicae Ether (myristicin) accounts for 9.05%, and ligustilide (ligustilide) accounts for 6.23%；Also containing terpinolene, cnidiumm lactone, 4-pine Oleyl alcohol, β-and ξ-guaiene, butylidenephthalide, Mentha piperita ketenes (piperitenone), australene, α ocimene (α- Ocimene), β-Luo Le alkene-Y, cumfrey (cumic acid), Isosorbide-5-Nitrae-ten one carbon diene (Isosorbide-5-Nitrae-undecadiene), α-, β-and ξ-elemene, elemicine, acetic acid Herba Cymbopogonis Citrari alcohol ester (citronellyl acetate), propanoic acid orange blossom alcohol ester (nerol Propionate), 2,3-dihydro-4,6,8-trimethyls-(2H)-naphthalene ketenes [2,3-dihydro-4,6,8-trimethyl- (2H)-naphthalenone][1].[pharmacological action] 1. effect to nervus centralis: Neutral Oil of Ligusticum sinense Oliv is with 1/10,1/5 half Dosage (median lethal dose(LD 50) of mouse stomach is 70.17 ± 4.95g (crude drug)/kg) gavage of lethal dose, can suppress mice spontaneous Activity, the locomotor stimulatory that antagonism amfetamine causes, strengthen the syngignoscism of penthiobarbital, the writhing that antagonism antimony potassium tartrate causes Reaction, extends the hot plate response time, reduces experimental heating rabbit body temperature and normal mouse body temperature.2. antiinflammatory: Neutral Oil of Ligusticum sinense Oliv 1/ 10,1/5 median lethal dose(LD 50) dosage (median lethal dose(LD 50) is ibid) gavage, the mice auricle swelling that suppression dimethylbenzene causes；Suppression angle The rat paw edema that fork dish glue causes.3. to intestinal and the effect of uterine smooth muscle: Neutral Oil of Ligusticum sinense Oliv 1.4 × 10-3-5.6 × 10- 3g/ml can suppress rabbit and the contraction of guinea pig in vitro intestinal tube, and can to antihistamine, acetylcholine, nicotine, physostigmine, phenol is appropriate draws Bright and barium chloride shrinks the effect of intestinal tube；70,140g/kg gavage, suppresses mouse small intestine ahead running, and also suppression Oleum Ricini causes Diarrhea of mouse；7 × 10-3-14 × 10-3g/ml suppresses rabbit isolated uterine, and can resist the effect in oxytocin excitement uterus. 1. bacteriostasis: 15% decoct plate dilution method, has inhibitory action to dermatophytosises such as achorion schoenleiniis.2. calm, analgesia, Antipyretic and antiinflammatory action: the mobility that 2.1. Neutral Oil of Ligusticum sinense Oliv can suppress the spontaneous activity of mice and antagonism amfetamine to cause is emerging Put forth energy, the syngignoscism of thiopentone can be strengthened, the mice that antimony potassium tartrate causes can be resisted and crook reaction and be obviously prolonged hot plate The time of reaction, and reduce the body temperature of pyrogenicity animal and the body temperature of normal mouse, moreover it is possible to antagonism dimethylbenzene inflammation.2.2. in Rhizoma Ligustici Property oil acetic acid can be suppressed to improve mouse peritoneal capillary permeability and histamine improve rat skin capillary permeability, suppression Dimethylbenzene induced mice auricular concha swelling, suppresses rat paw edema caused by carrageenin and extracts adrenal gland rat injection chondrus ocellatus Holmes Pedal swelling caused by glue.But rat plastic hoop granuloma hypertrophy can not be suppressed, the life extracing adrenal gland rat can not be extended Deposit the time.Point out its anti-inflammatory effect and pituitary-adrenal system without obvious relation, thus it is speculated that it may be by suppressing prostatitis Parathyrine produces antiinflammatory action.2.3. in Rhizoma Ligustici one of composition ferulic acid (Ferulicacid) can reduce crook reaction and extend ring The length of one's sleep of hexene barbital sodium, additionally, another composition ligustilide to have calmness, hypnosis, cooling and anti-ketamine emerging The effect of putting forth energy.3. smooth muscle effect: 3.1. is to intestinal and the inhibitory action of uterine smooth muscle: Neutral Oil of Ligusticum sinense Oliv has suppression isolated rabbit small intestinal Contractive amplitude, suppression isolated guinea pig ileum tension force, the effect of suppression isolated rabbit uterus tension force；Can also be to antihistaminic, acetyl The intestinal activity that choline, nicotine, physostigmine, phentolamine and barium chloride cause is excited, and the uterus muscle that antagonism oxytocin causes is opened Power increases and becomes；May also suppress mouse small intestine ahead running, the diarrhea of mouse that suppression Oleum Ricini causes.Result shows, Neutral Oil of Ligusticum sinense Oliv There is suppression intestinal and the effect of uterine smooth muscle.3.2. antiasthmatic effect: the antiasthmatic effect of 3.2.1. Rhizoma Ligustici lactone: to Cavia porcellus abdominal cavity Injection 0.14ml/kg ligustilide can be alleviated the cause of histamine and acetylcholine and breathes heavily reaction, its effect about with aminophylline 50mg/ Kg is similar, tests in Guinea pig lung overflow, and intravenous injection ligustilide 0.08ml/kg can be to caused by antihistaminic 2-10 μ g/kg Bronchoconstriction.Ligustilide not only has a relaxation effect to isolated helical strips of guinea, and to acetylcholine, histamine and The tracheal smooth muscle spasm that barium chloride causes shrinks, and has obvious spasmolysis.This effect can not be blocked by propranolol.Rhizoma Ligustici The content of cAMP and cGMP in Guinea pig lung, intestinal tissue is all had no significant effect by lactone, it is believed that likely act on smooth muscle itself. 3.2.2. Phthalide and the antiasthmatic effect of derivant thereof: Phthalide and derivant vinyl lactone, acrylic husband's lactone, n-butene husband Lactone and normal-butyl husband's lactone are respectively provided with significant relexation to animal tracheal smooth muscle.Its action intensity is final without the poorest Different, it is believed that n-butene husband's lactone and the antiasthmatic effect of homologue thereof, had by its parent nucleus Phthalide, the effect speed of six kinds of compounds Spend between its chemical constitution, like regular change, wherein with Phthalide and vinyl lactone for the soonest, along with the growth of side chain Seemingly there is the trend slowed down.It is fast for not having normal-butyl husband's lactone speed of action of double bond and relatively having n-butene husband's lactone of double bond.Benzene The relax effect of tracheal smooth muscle of phthalein not by beta-receptor on excited tracheal smooth muscle or promotes adrenergic nerve release Caused by medium.It is little with M mono-cholinoceptor and histamine receptor relation.Phthalide can be rapid and significant resist the work of barium chloride With, show that it is probably directly effect and makes tracheal smooth muscle relax.Above-claimed cpd is respectively provided with certain toxicity and to gastrointestinal tract Stimulation.[nature and flavor] acrid in the mouth；Property is wet.[return through] returns bladder warp, [function cures mainly] expelling wind and dampness；Dispersing cold for relieving pain.Main air is trembled with fear Headache；Top, mountain peak pain；Rheumatic arthralgia；Scabies；Cold-damp is had loose bowels；Stomachache；Hernia abdominal mass, [extracts] " China's book on Chinese herbal medicine ".
Sanya aluminum oleate (Aluminium Trilinoleate): molecular formula: C54H93AlO6,Molecular weight: 865.31, CAS Accession number: 645-17-0.Boiling point: 360.6 ° of Cat 760 mmHg, flash-point: 273 ° of C (value of calculation).
Flos Woodfordiae Fruticosae tannin A(Woodfordin A): molecular formula: C75H56O48,Molecular weight: 1725.24, CAS accession number: 127243-65-6.Density: 2.18g/cm3 。
Summary of the invention
It is an object of the invention to overcome the deficiency of background technology, it is provided that the medicine of a kind of effective treatment Posterior circulation ischemia syndrome Compositions and preparation method thereof.
The present invention adopts the following technical scheme that realization:
Composition and the weight portion of making the crude drug of the pharmaceutical composition of this treatment Posterior circulation ischemia syndrome be:
Radix Et Rhizoma Fagopyri Tatarici 5550 5650g, Medulla Tetrapanacis 850 950g, Fructus Schisandrae Chinensis 1050 1150g, Rhizoma Drynariae 1350 1450g, Rhizoma Ligustici 2150 2250g, Sanya aluminum oleate 25 35g, Flos Woodfordiae Fruticosae tannin A88 98g.
It is preferably used in the pharmaceutical composition for the treatment of Posterior circulation ischemia syndrome, is by the crude drug group of following weight portion Become:
Radix Et Rhizoma Fagopyri Tatarici 5600g, Medulla Tetrapanacis 900g, Fructus Schisandrae Chinensis 1100g, Rhizoma Drynariae 1400g, Rhizoma Ligustici 2200g, Sanya aluminum oleate 30g, shrimp-roe Flower tannin A92g.
A kind of pharmaceutical composition treating Posterior circulation ischemia syndrome, it is characterised in that pharmaceutical composition can use preparation The conventional method learned is prepared as tablet or capsule or drop pill.
A kind of pharmaceutical composition treating Posterior circulation ischemia syndrome, it is characterised in that pharmaceutical composition and chemical drugs or in The treatment Posterior circulation ischemia syndrome medicine of medicine composition.
The preparation method of a kind of pharmaceutical composition treating Posterior circulation ischemia syndrome, it is characterised in that make as follows Standby:
The composition of crude drug and weight portion be: Radix Et Rhizoma Fagopyri Tatarici 5550 5650g, Medulla Tetrapanacis 850 950g, Fructus Schisandrae Chinensis 1050 1150g, Rhizoma Drynariae 1350 1450g, Rhizoma Ligustici 2150 2250g, Sanya aluminum oleate 25 35g, Flos Woodfordiae Fruticosae tannin A88 98g；
Preparation method:
(1) Radix Et Rhizoma Fagopyri Tatarici, Medulla Tetrapanacis, Fructus Schisandrae Chinensis, Rhizoma Drynariae, Rhizoma Ligustici, Sanya aluminum oleate, Flos Woodfordiae Fruticosae tannin A are taken by crude drug proportioning, mixed Even, with weight percent concentration 32% ethanol as solvent, extract at 46 DEG C of warm macerating, extraction time is 12 times, each extraction time Being 18 hours, each solvent load is 41 times of crude drug gross weight, filters, obtains medicinal residues A and extracting solution A, and extracting solution A reclaims second Alcohol, is concentrated into relative density 1.18, filters, and medicinal liquid passes through LSA-40 macroporous adsorptive resins, first washes with water, then by weight hundred Proportion by subtraction concentration 68% ethanol solution eluting LSA-40 macroporous adsorptive resins, collects weight percent concentration 68% ethanol elution, Reclaim ethanol, concentrate drying, obtain extract A；
(2) take step (1) medicinal residues A, with weight percent concentration 57% ethanol as solvent, heating and refluxing extraction 7 times, carry every time The time of taking is 3 hours, and each solvent load is 13 times of medicinal residues A weight, filters, and obtains medicinal residues B and extracting solution B, extracting solution B and reclaims Ethanol, is concentrated into relative density 1.11, filters, and medicinal liquid passes through DM11 macroporous adsorptive resins, first washes with water, then by weight hundred Proportion by subtraction concentration 70% ethanol solution eluting DM11 macroporous adsorptive resins, collects weight percent concentration 70% ethanol elution, returns Receive ethanol, concentrate drying, obtain extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
The preparation method of a kind of pharmaceutical composition treating Posterior circulation ischemia syndrome, it is characterised in that by as follows Prepared by step:
The composition of crude drug and weight portion be: Radix Et Rhizoma Fagopyri Tatarici 5600g, Medulla Tetrapanacis 900g, Fructus Schisandrae Chinensis 1100g, Rhizoma Drynariae 1400g, Rhizoma Ligustici 2200g, Sanya aluminum oleate 30g, Flos Woodfordiae Fruticosae tannin A92g；
Preparation method:
(1) Radix Et Rhizoma Fagopyri Tatarici, Medulla Tetrapanacis, Fructus Schisandrae Chinensis, Rhizoma Drynariae, Rhizoma Ligustici, Sanya aluminum oleate, Flos Woodfordiae Fruticosae tannin A are taken by crude drug proportioning, mixed Even, with weight percent concentration 32% ethanol as solvent, extract at 46 DEG C of warm macerating, extraction time is 12 times, each extraction time Being 18 hours, each solvent load is 41 times of crude drug gross weight, filters, obtains medicinal residues A and extracting solution A, and extracting solution A reclaims second Alcohol, is concentrated into relative density 1.18, filters, and medicinal liquid passes through LSA-40 macroporous adsorptive resins, first washes with water, then by weight hundred Proportion by subtraction concentration 68% ethanol solution eluting LSA-40 macroporous adsorptive resins, collects weight percent concentration 68% ethanol elution, Reclaim ethanol, concentrate drying, obtain extract A；
(2) take step (1) medicinal residues A, with weight percent concentration 57% ethanol as solvent, heating and refluxing extraction 7 times, carry every time The time of taking is 3 hours, and each solvent load is 13 times of medicinal residues A weight, filters, and obtains medicinal residues B and extracting solution B, extracting solution B and reclaims Ethanol, is concentrated into relative density 1.11, filters, and medicinal liquid passes through DM11 macroporous adsorptive resins, first washes with water, then by weight hundred Proportion by subtraction concentration 70% ethanol solution eluting DM11 macroporous adsorptive resins, collects weight percent concentration 70% ethanol elution, returns Receive ethanol, concentrate drying, obtain extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
The preparation method of a kind of pharmaceutical composition treating Posterior circulation ischemia syndrome, it is characterised in that pharmaceutical composition can To use the conventional method of galenic pharmacy to be prepared as tablet or capsule or drop pill.
A kind of preparation method of the pharmaceutical composition treating Posterior circulation ischemia syndrome, it is characterised in that pharmaceutical composition with Chemical drugs or Chinese medicine composition treatment Posterior circulation ischemia syndrome medicine.
Detailed description of the invention
Embodiment 1: pharmaceutical composition for the treatment of Posterior circulation ischemia syndrome and preparation method thereof
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of Posterior circulation ischemia syndrome be: Radix Et Rhizoma Fagopyri Tatarici 5600g, Medulla Tetrapanacis 900g, Fructus Schisandrae Chinensis 1100g, Rhizoma Drynariae 1400g, Rhizoma Ligustici 2200g, Sanya aluminum oleate 30g, Flos Woodfordiae Fruticosae tannin A92g；
Preparation method:
(1) Radix Et Rhizoma Fagopyri Tatarici, Medulla Tetrapanacis, Fructus Schisandrae Chinensis, Rhizoma Drynariae, Rhizoma Ligustici, Sanya aluminum oleate, Flos Woodfordiae Fruticosae tannin A are taken by crude drug proportioning, mixed Even, with weight percent concentration 32% ethanol as solvent, extract at 46 DEG C of warm macerating, extraction time is 12 times, each extraction time Being 18 hours, each solvent load is 41 times of crude drug gross weight, filters, obtains medicinal residues A and extracting solution A, and extracting solution A reclaims second Alcohol, is concentrated into relative density 1.18, filters, and medicinal liquid passes through LSA-40 macroporous adsorptive resins, first washes with water, then by weight hundred Proportion by subtraction concentration 68% ethanol solution eluting LSA-40 macroporous adsorptive resins, collects weight percent concentration 68% ethanol elution, Reclaim ethanol, concentrate drying, obtain extract A；
(2) take step (1) medicinal residues A, with weight percent concentration 57% ethanol as solvent, heating and refluxing extraction 7 times, carry every time The time of taking is 3 hours, and each solvent load is 13 times of medicinal residues A weight, filters, and obtains medicinal residues B and extracting solution B, extracting solution B and reclaims Ethanol, is concentrated into relative density 1.11, filters, and medicinal liquid passes through DM11 macroporous adsorptive resins, first washes with water, then by weight hundred Proportion by subtraction concentration 70% ethanol solution eluting DM11 macroporous adsorptive resins, collects weight percent concentration 70% ethanol elution, returns Receive ethanol, concentrate drying, obtain extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
Embodiment 2: pharmaceutical composition for the treatment of Posterior circulation ischemia syndrome and preparation method thereof
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of Posterior circulation ischemia syndrome be: Radix Et Rhizoma Fagopyri Tatarici 5550g, Medulla Tetrapanacis 950g, Fructus Schisandrae Chinensis 1050g, Rhizoma Drynariae 1450g, Rhizoma Ligustici 2150g, Sanya aluminum oleate 35g, Flos Woodfordiae Fruticosae tannin A88g；
Preparation method:
(1) Radix Et Rhizoma Fagopyri Tatarici, Medulla Tetrapanacis, Fructus Schisandrae Chinensis, Rhizoma Drynariae, Rhizoma Ligustici, Sanya aluminum oleate, Flos Woodfordiae Fruticosae tannin A are taken by crude drug proportioning, mixed Even, with weight percent concentration 32% ethanol as solvent, extract at 46 DEG C of warm macerating, extraction time is 12 times, each extraction time Being 18 hours, each solvent load is 41 times of crude drug gross weight, filters, obtains medicinal residues A and extracting solution A, and extracting solution A reclaims second Alcohol, is concentrated into relative density 1.18, filters, and medicinal liquid passes through LSA-40 macroporous adsorptive resins, first washes with water, then by weight hundred Proportion by subtraction concentration 68% ethanol solution eluting LSA-40 macroporous adsorptive resins, collects weight percent concentration 68% ethanol elution, Reclaim ethanol, concentrate drying, obtain extract A；
(2) take step (1) medicinal residues A, with weight percent concentration 57% ethanol as solvent, heating and refluxing extraction 7 times, carry every time The time of taking is 3 hours, and each solvent load is 13 times of medicinal residues A weight, filters, and obtains medicinal residues B and extracting solution B, extracting solution B and reclaims Ethanol, is concentrated into relative density 1.11, filters, and medicinal liquid passes through DM11 macroporous adsorptive resins, first washes with water, then by weight hundred Proportion by subtraction concentration 70% ethanol solution eluting DM11 macroporous adsorptive resins, collects weight percent concentration 70% ethanol elution, returns Receive ethanol, concentrate drying, obtain extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
Embodiment 3: pharmaceutical composition for the treatment of Posterior circulation ischemia syndrome and preparation method thereof
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of Posterior circulation ischemia syndrome be: Radix Et Rhizoma Fagopyri Tatarici 5650g, Medulla Tetrapanacis 850g, Fructus Schisandrae Chinensis 1150g, Rhizoma Drynariae 1350g, Rhizoma Ligustici 2250g, Sanya aluminum oleate 25g, Flos Woodfordiae Fruticosae tannin A98g；
Preparation method:
(1) Radix Et Rhizoma Fagopyri Tatarici, Medulla Tetrapanacis, Fructus Schisandrae Chinensis, Rhizoma Drynariae, Rhizoma Ligustici, Sanya aluminum oleate, Flos Woodfordiae Fruticosae tannin A are taken by crude drug proportioning, mixed Even, with weight percent concentration 32% ethanol as solvent, extract at 46 DEG C of warm macerating, extraction time is 12 times, each extraction time Being 18 hours, each solvent load is 41 times of crude drug gross weight, filters, obtains medicinal residues A and extracting solution A, and extracting solution A reclaims second Alcohol, is concentrated into relative density 1.18, filters, and medicinal liquid passes through LSA-40 macroporous adsorptive resins, first washes with water, then by weight hundred Proportion by subtraction concentration 68% ethanol solution eluting LSA-40 macroporous adsorptive resins, collects weight percent concentration 68% ethanol elution, Reclaim ethanol, concentrate drying, obtain extract A；
(2) take step (1) medicinal residues A, with weight percent concentration 57% ethanol as solvent, heating and refluxing extraction 7 times, carry every time The time of taking is 3 hours, and each solvent load is 13 times of medicinal residues A weight, filters, and obtains medicinal residues B and extracting solution B, extracting solution B and reclaims Ethanol, is concentrated into relative density 1.11, filters, and medicinal liquid passes through DM11 macroporous adsorptive resins, first washes with water, then by weight hundred Proportion by subtraction concentration 70% ethanol solution eluting DM11 macroporous adsorptive resins, collects weight percent concentration 70% ethanol elution, returns Receive ethanol, concentrate drying, obtain extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
Embodiment 4: the preparation of tablet
Example 1 pharmaceutical composition 312g, adds starch 98g, mixing, pelletizes, be dried, add microcrystalline Cellulose 35g, stearic acid Magnesium 3g, mixing, it is pressed into 1000, obtains medicinal composition tablets.
Embodiment 5: the preparation of capsule
Example 2 pharmaceutical composition 304g, adds starch 98g, mixing, pelletizes, be dried, granulate, add appropriate magnesium stearate, Mixing, obtains medicament composition capsule by encapsulated 1000.
Embodiment 6: the preparation of drop pill
Weigh polyethylene glycol 6000 193g water-bath (80 DEG C) heating and boil molten, add embodiment 3 pharmaceutical composition 14g, fully stir Mixing uniformly, with liquid paraffin as coolant, put in glass tubing (4*80cm), chilling temperature is 5 DEG C, and drip internal-and external diameter is 7.0/ 2.0 (mm/mm), drip is 2.5cm away from liquid level, drips fast with 58 every point as optimum condition, blots the cold of drop pill surface with cotton Solidifying agent, obtains medicament composition dropping pills.
Embodiment 7: the pharmaceutical composition for the treatment of Posterior circulation ischemia syndrome
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of Posterior circulation ischemia syndrome be:
Radix Et Rhizoma Fagopyri Tatarici 3200g, Medulla Tetrapanacis 2100g, Sanya aluminum oleate 45g, Flos Woodfordiae Fruticosae tannin A37g.
Embodiment 8: the pharmaceutical composition for the treatment of Posterior circulation ischemia syndrome
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of Posterior circulation ischemia syndrome be:
Radix Et Rhizoma Fagopyri Tatarici 3150g, Medulla Tetrapanacis 2150g, Sanya aluminum oleate 40g, Flos Woodfordiae Fruticosae tannin A42g.
Embodiment 9: the pharmaceutical composition for the treatment of Posterior circulation ischemia syndrome
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of Posterior circulation ischemia syndrome be:
Radix Et Rhizoma Fagopyri Tatarici 3250g, Medulla Tetrapanacis 2050g, Sanya aluminum oleate 50g, Flos Woodfordiae Fruticosae tannin A32g.
Experimental example 1: the experimental study for the treatment of Posterior circulation ischemia syndrome
L physical data: the 100 example Posterior circulation ischemia choosing Huanhu Hospital, Tianjin City's in June, 2015～in November, 2015 treatment are combined Simulator sickness patient is experimental subject；It is divided into observation group 50 example and matched group 50 example, male 25 example, female in observation group according to medicining condition Property 25 examples, patient age 41 years old～68 years old, 5 2.28 ± 5.46 years old mean age；Male 25 example in matched group, women 25 example, Patient age 40 years old～68 years old, 52.22 ± 5.15 years old mean age；In this experiment, the basic disease of main foundation is coronary heart disease 36 Example, hypertension 34 example, 30 Cases of Diabetes Mellitus.Case selection standard: (1) meets WHO cerebrovascular dependent diagnostic standard, bright Really it is diagnosed as Posterior circulation ischemia syndrome；(2) without cardiopulmonary hepatic renal dysfunction, cerebral hemorrhage and bleeding tendency；(3) do not take molten Bolt is treated；(4) it is correlated with contraindication without medicine.The age of 2 groups of patients, sex, the course of disease and the state of an illness without significant difference (P > 0.05)。
2 Therapeutic Method: matched group: (1) gives to control blood pressure and blood sugar, correct the conventional therapies such as Electrolyte imbalance；(2 ) Give vinpocetine: (trade name unit is appropriate, traditional Chinese medicines quasi-word H20051588, Guangdong Bada Pharmaceutical Co., Ltd.), injection Chang Chunxi Spit of fland 20m g+normal saline 250m L, intravenous drip, every day 1 time, 14 days is 1 course for the treatment of.Observation group: on the basis of matched group This pharmaceutical composition (embodiment 1 pharmaceutical composition lot number 20140811), each 2g are administered orally simultaneously, every day 2 times, are used in conjunction 2 weeks.
3 evaluation indexes: therapeutic effect is evaluated by reference literature report: (1) fully recovers: clinical symptoms and sign are thorough Disappearing, hemodynamics detection confirms that vertebra one basilar artery blood flow is normal, has normal work and operational forces；(2) effective: Clinical symptoms and sign major part disappear, and hemodynamics detection prompting vertebra one basilar artery blood flow is obviously improved, and has base This ADL；(3) effective: sings and symptoms makes moderate progress, hemodynamics detection prompting vertebra one basilar artery blood Stream part takes a turn for the better, and daily work and working portion are limited；(4) invalid: clinical symptoms and sign have no improvement or increase the weight of, vertebra base End artery blood flow is without improving or deteriorating.Total effective rate=cure rate+obvious effective rate+effective percentage.
4 statistical procedures: data analysis SPSS16.0 statistics software, enumeration data represents with percentage rate, uses x2Inspection, P < 0.05, difference has significance.
5 results: observation group fully recovers 20 examples, and cure rate is 40%, effective 18 examples, and obvious effective rate is 36%, effective 9 examples, effectively Rate is 18%, invalid 3 examples, and total effective rate is 94%, and matched group is fully recovered 5 examples, and cure rate is 10%, effective 10 examples, and obvious effective rate is 20%, effective 22 examples, effective percentage is 44%, invalid 13 examples, total effective rate 74%, through statistics software analysis, P < 0.05,2 Group data have significant difference.
Experimental example 2: model case
Grandson XX, female, 54 years old, Posterior circulation ischemia syndrome patient, mainly performance: dizzy, Head And Face numbness, limb adynamia, headache, Walking shakiness.Dysphagia, the visual field are unclear.(embodiment 1 pharmaceutical composition is criticized to start pharmaceutical composition on April 18th, 2016 Numbers 20140811), each 2g, every day 2 times, be used in conjunction 8 weeks, the clinical symptoms of grandson disappears substantially, after continue to take 2 weeks, all shapes Disappear the same with normal person.
Old XX, man, 49 years old, cervical spondylosis Posterior circulation ischemia patient, falls ill, have a headache, time serious five during morbidity in October, 2015 Dirty six internal organs pain, eyes are particularly acute.On October 18th, 2016 starts pharmaceutical composition (embodiment 1 pharmaceutical composition lot number 20140811), each 2g, every day 2 times, be used in conjunction 8 weeks, the clinical symptoms of Chen disappears substantially, after continue to take 2 weeks, all shapes disappear Lose, thoroughly cure.

Claims (8)

1. the pharmaceutical composition treating Posterior circulation ischemia syndrome, it is characterised in that make the crude drug of this pharmaceutical composition Composition and weight portion be:
Radix Et Rhizoma Fagopyri Tatarici 5550 5650g, Medulla Tetrapanacis 850 950g, Fructus Schisandrae Chinensis 1050 1150g, Rhizoma Drynariae 1350 1450g, Rhizoma Ligustici 2150 2250g, Sanya aluminum oleate 25 35g, Flos Woodfordiae Fruticosae tannin A88 98g.
A kind of pharmaceutical composition treating Posterior circulation ischemia syndrome, it is characterised in that make this The composition of the crude drug of pharmaceutical composition and weight portion be:
Radix Et Rhizoma Fagopyri Tatarici 5600g, Medulla Tetrapanacis 900g, Fructus Schisandrae Chinensis 1100g, Rhizoma Drynariae 1400g, Rhizoma Ligustici 2200g, Sanya aluminum oleate 30g, shrimp-roe Flower tannin A92g.
A kind of pharmaceutical composition treating Posterior circulation ischemia syndrome, it is characterised in that medicine group Compound can use the conventional method of galenic pharmacy to be prepared as tablet or capsule or drop pill.
A kind of pharmaceutical composition treating Posterior circulation ischemia syndrome, it is characterised in that medicine group Compound and chemical drugs or the treatment Posterior circulation ischemia syndrome medicine of Chinese medicine composition.
5. the preparation method of the pharmaceutical composition treating Posterior circulation ischemia syndrome, it is characterised in that make as follows Standby:
The composition of crude drug and weight portion be: Radix Et Rhizoma Fagopyri Tatarici 5550 5650g, Medulla Tetrapanacis 850 950g, Fructus Schisandrae Chinensis 1050 1150g, Rhizoma Drynariae 1350 1450g, Rhizoma Ligustici 2150 2250g, Sanya aluminum oleate 25 35g, Flos Woodfordiae Fruticosae tannin A88 98g；
Preparation method:
(1) Radix Et Rhizoma Fagopyri Tatarici, Medulla Tetrapanacis, Fructus Schisandrae Chinensis, Rhizoma Drynariae, Rhizoma Ligustici, Sanya aluminum oleate, Flos Woodfordiae Fruticosae tannin A are taken by crude drug proportioning, mixed Even, with weight percent concentration 32% ethanol as solvent, extract at 46 DEG C of warm macerating, extraction time is 12 times, each extraction time Being 18 hours, each solvent load is 41 times of crude drug gross weight, filters, obtains medicinal residues A and extracting solution A, and extracting solution A reclaims second Alcohol, is concentrated into relative density 1.18, filters, and medicinal liquid passes through LSA-40 macroporous adsorptive resins, first washes with water, then by weight hundred Proportion by subtraction concentration 68% ethanol solution eluting LSA-40 macroporous adsorptive resins, collects weight percent concentration 68% ethanol elution, Reclaim ethanol, concentrate drying, obtain extract A；
(2) take step (1) medicinal residues A, with weight percent concentration 57% ethanol as solvent, heating and refluxing extraction 7 times, carry every time The time of taking is 3 hours, and each solvent load is 13 times of medicinal residues A weight, filters, and obtains medicinal residues B and extracting solution B, extracting solution B and reclaims Ethanol, is concentrated into relative density 1.11, filters, and medicinal liquid passes through DM11 macroporous adsorptive resins, first washes with water, then by weight hundred Proportion by subtraction concentration 70% ethanol solution eluting DM11 macroporous adsorptive resins, collects weight percent concentration 70% ethanol elution, returns Receive ethanol, concentrate drying, obtain extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
A kind of preparation method of the pharmaceutical composition treating Posterior circulation ischemia syndrome, its feature It is to prepare as follows:
The composition of crude drug and weight portion be: Radix Et Rhizoma Fagopyri Tatarici 5600g, Medulla Tetrapanacis 900g, Fructus Schisandrae Chinensis 1100g, Rhizoma Drynariae 1400g, Rhizoma Ligustici 2200g, Sanya aluminum oleate 30g, Flos Woodfordiae Fruticosae tannin A92g；
Preparation method:
(1) Radix Et Rhizoma Fagopyri Tatarici, Medulla Tetrapanacis, Fructus Schisandrae Chinensis, Rhizoma Drynariae, Rhizoma Ligustici, Sanya aluminum oleate, Flos Woodfordiae Fruticosae tannin A are taken by crude drug proportioning, mixed Even, with weight percent concentration 32% ethanol as solvent, extract at 46 DEG C of warm macerating, extraction time is 12 times, each extraction time Being 18 hours, each solvent load is 41 times of crude drug gross weight, filters, obtains medicinal residues A and extracting solution A, and extracting solution A reclaims second Alcohol, is concentrated into relative density 1.18, filters, and medicinal liquid passes through LSA-40 macroporous adsorptive resins, first washes with water, then by weight hundred Proportion by subtraction concentration 68% ethanol solution eluting LSA-40 macroporous adsorptive resins, collects weight percent concentration 68% ethanol elution, Reclaim ethanol, concentrate drying, obtain extract A；
(2) take step (1) medicinal residues A, with weight percent concentration 57% ethanol as solvent, heating and refluxing extraction 7 times, carry every time The time of taking is 3 hours, and each solvent load is 13 times of medicinal residues A weight, filters, and obtains medicinal residues B and extracting solution B, extracting solution B and reclaims Ethanol, is concentrated into relative density 1.11, filters, and medicinal liquid passes through DM11 macroporous adsorptive resins, first washes with water, then by weight hundred Proportion by subtraction concentration 70% ethanol solution eluting DM11 macroporous adsorptive resins, collects weight percent concentration 70% ethanol elution, returns Receive ethanol, concentrate drying, obtain extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
A kind of preparation method of the pharmaceutical composition treating Posterior circulation ischemia syndrome, its feature It is that pharmaceutical composition can use the conventional method of galenic pharmacy to be prepared as tablet or capsule or drop pill.
A kind of preparation method of the pharmaceutical composition treating Posterior circulation ischemia syndrome, its feature It is pharmaceutical composition and chemical drugs or Chinese medicine composition treatment Posterior circulation ischemia syndrome medicine.
CN201610505361.0A 2016-07-01 2016-07-01 Medicine composition for treating posterior circulation ischemia syndrome and preparation method thereof Withdrawn CN106038791A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610505361.0A CN106038791A (en) 2016-07-01 2016-07-01 Medicine composition for treating posterior circulation ischemia syndrome and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610505361.0A CN106038791A (en) 2016-07-01 2016-07-01 Medicine composition for treating posterior circulation ischemia syndrome and preparation method thereof

Publications (1)

Publication Number Publication Date
CN106038791A true CN106038791A (en) 2016-10-26

Family

ID=57201392

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610505361.0A Withdrawn CN106038791A (en) 2016-07-01 2016-07-01 Medicine composition for treating posterior circulation ischemia syndrome and preparation method thereof

Country Status (1)

Country Link
CN (1) CN106038791A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106692668A (en) * 2016-12-10 2017-05-24 济南昊雨青田医药技术有限公司 Drug composition for treating Aids and preparation method of drug composition
CN106728513A (en) * 2016-12-10 2017-05-31 济南昊雨青田医药技术有限公司 It is a kind of to treat pharmaceutical composition of AIDS and preparation method thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106692668A (en) * 2016-12-10 2017-05-24 济南昊雨青田医药技术有限公司 Drug composition for treating Aids and preparation method of drug composition
CN106728513A (en) * 2016-12-10 2017-05-31 济南昊雨青田医药技术有限公司 It is a kind of to treat pharmaceutical composition of AIDS and preparation method thereof

Similar Documents

Publication Publication Date Title
CN104435775A (en) Chinese medicinal health-care spirit and preparation method thereof
CN102784363A (en) Traditional Chinese medicine composition for treating pancreatic cancer and preparation method thereof
CN105454576A (en) Jasmine-flower-comprising assorted Chinese herbal tea and preparation method thereof
CN105124078A (en) Gardenia blood-glucose-reducing and lipid-reducing healthcare tea and preparing method thereof
CN103656072A (en) Traditional Chinese medicine composition for prompting pregnancy and preparation method thereof
CN106038791A (en) Medicine composition for treating posterior circulation ischemia syndrome and preparation method thereof
CN103705638B (en) Chinese medicine composition of a kind of alleviating asthenopia and preparation method thereof
CN105267906A (en) Compound chocolate Chinese herbal composition for treating and improving menstrual syndrome of females
CN105482965B (en) A kind of health-care white spirit and preparation method thereof
CN103656195A (en) Traditional Chinese medicine composition for treatment of kidney deficiency and preparation method thereof
CN103272125A (en) Traditional Chinese medicine composition containing dendrobium huoshanense and having hypoglycemic effect, and preparation method thereof
CN105748901A (en) Formula and preparation method of health-care beverage
CN105062810A (en) Saussurea involucrate prepared wine and preparation method thereof
CN104800601A (en) Traditional Chinese medicine for treating cerebral arteriosclerosis
CN107812115A (en) A kind of Chinese medicine composition for treating diabetes
CN103656197B (en) The Chinese medicine composition of kidney tonifying and enriching blood and preparation method
CN105535243A (en) Medicine for treating intractable constipation
CN109528984A (en) A kind of cream formula and preparation method by smearing breast treatment mammary gland disease
CN107929524A (en) A kind of coltsfoot frondosa oral liquid of lowering blood-fat and reducing weight and preparation method thereof
CN109568496B (en) Detection method of traditional Chinese medicine composition for treating diabetes
CN107669576A (en) A kind of cosmetic composition for improving proliferation of mammary gland prevention mammary gland disease
CN105012731A (en) Traditional Chinese medicine for preventing postpartum hemorrhage and preparation method of traditional Chinese medicine
CN106074773A (en) A kind of pharmaceutical composition treating diabetes constipation and preparation method thereof
CN105891401B (en) Money Hymecromone granular mass control method
CN105288166A (en) Traditional Chinese medicine composition for thyroid enlargement and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20161026

WW01 Invention patent application withdrawn after publication